ZA991369B - Immunological methods to modulate myostatin in vertebrate subjects. - Google Patents

Immunological methods to modulate myostatin in vertebrate subjects.

Info

Publication number
ZA991369B
ZA991369B ZA9901369A ZA991369A ZA991369B ZA 991369 B ZA991369 B ZA 991369B ZA 9901369 A ZA9901369 A ZA 9901369A ZA 991369 A ZA991369 A ZA 991369A ZA 991369 B ZA991369 B ZA 991369B
Authority
ZA
South Africa
Prior art keywords
immunological methods
vertebrate subjects
modulate myostatin
myostatin
modulate
Prior art date
Application number
ZA9901369A
Other languages
English (en)
Inventor
Christopher A Barker
Mohamad Morsey
Original Assignee
Biostar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostar Inc filed Critical Biostar Inc
Publication of ZA991369B publication Critical patent/ZA991369B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA9901369A 1998-02-19 1999-02-19 Immunological methods to modulate myostatin in vertebrate subjects. ZA991369B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7521398P 1998-02-19 1998-02-19

Publications (1)

Publication Number Publication Date
ZA991369B true ZA991369B (en) 1999-08-20

Family

ID=22124285

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901369A ZA991369B (en) 1998-02-19 1999-02-19 Immunological methods to modulate myostatin in vertebrate subjects.

Country Status (18)

Country Link
US (2) US6369201B1 (de)
EP (3) EP1056845B1 (de)
JP (1) JP2002504326A (de)
KR (1) KR20010041111A (de)
AR (1) AR019818A1 (de)
AT (2) ATE419353T1 (de)
AU (1) AU765014B2 (de)
BR (1) BR9907995A (de)
CA (2) CA2323607C (de)
CY (2) CY1108074T1 (de)
DE (2) DE69940230D1 (de)
DK (2) DK1770162T3 (de)
ES (3) ES2318654T3 (de)
IL (1) IL137831A0 (de)
NZ (1) NZ506911A (de)
PT (2) PT1056845E (de)
WO (1) WO1999042573A1 (de)
ZA (1) ZA991369B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US7566768B1 (en) * 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
EP0690873B1 (de) 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Wachstumsfaktor-8
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
EP1147413B1 (de) * 1999-01-21 2006-04-05 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
AU778470B2 (en) * 1999-07-20 2004-12-09 Pharmexa A/S Method for down-regulating GDF-8 activity
ZA200003786B (en) 1999-07-30 2002-01-21 Pfizer Prod Inc Myostatin regulatory region, nucleotide sequence determination and methods for its use.
EP1593689A3 (de) * 2000-01-18 2006-04-05 Ovita Limited Myostatin und dessen Mimetika
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP4429728B2 (ja) * 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン(follistatin)ドメイン含有タンパク質
BR0307907A2 (pt) * 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
JP4547561B2 (ja) * 2002-09-16 2010-09-22 ザ ジョンズ ホプキンス ユニバーシティー メタロプロテアーゼによるミオスタチンの活性化、およびミオスタチン活性の調節法
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
US7785587B2 (en) * 2003-06-02 2010-08-31 Wyeth Therapeutic methods for muscular or neuromuscular disorders
US7371726B2 (en) * 2003-12-31 2008-05-13 Schering-Plough Animal Health Corporation Neutralizing GDF8 epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
EP1778275A2 (de) * 2004-08-12 2007-05-02 Wyeth Kombinationstherapie für diabetes, adipositas und herz-kreislauf-erkrankungen unter verwendung von gdf-8-hemmern
WO2006036074A1 (en) * 2004-09-30 2006-04-06 Orico Limited Myostatin isoform
JP2008526201A (ja) * 2004-12-30 2008-07-24 シェーリング−プラウ・リミテッド 中和エピトープベースの成長増強ワクチン
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
CA2601086A1 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to gdf-8 modulating agents
AU2006321906C1 (en) * 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
CA2693378C (en) * 2006-08-03 2020-04-14 Orico Limited Myostatin antagonists
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
EP2066695B1 (de) 2006-09-05 2013-03-27 Eli Lilly And Company Anti-myostatin-antikörper
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
EP3711771A1 (de) 2012-08-01 2020-09-23 Ikaika Therapeutics, LLC Abschwächung von gewebeverletzungen und fibrose mithilfe des latenten transformierenden wachstumsfaktor-beta-bindenden proteins (ltbp4)
CN104391628B (zh) * 2014-04-02 2018-02-23 贵阳朗玛信息技术股份有限公司 进程切换方法及装置
EP2960653A1 (de) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnosekit und Verfahren zur Identifizierung der Manipulation der Muskelmasse bei einem Haustier
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
CA3131959A1 (en) * 2019-03-01 2020-09-10 Knc Laboratories Co., Ltd. Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1605763A (en) 1926-11-02 Garment retainer
US2754818A (en) 1950-06-24 1956-07-17 Scherer Corp R P Hypo jet injector
US3330276A (en) 1963-10-07 1967-07-11 Scherer Corp R P Hypodermic jet injector
US3788315A (en) 1971-04-20 1974-01-29 S Laurens Disposable cutaneous transjector
US3853125A (en) 1971-10-05 1974-12-10 W Clark Disposable needleless injector
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
EP0043718B1 (de) 1980-07-07 1984-11-28 National Research Development Corporation Zellinien
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
JPS5873993U (ja) 1981-11-12 1983-05-19 三菱電機株式会社 2気筒回転式圧縮機
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4518385A (en) 1983-06-13 1985-05-21 Preci-Tech Ltd. Disposable syringe for needleless injector
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5062830A (en) 1990-04-04 1991-11-05 Derata Corporation Dry disposable nozzle assembly for medical jet injector
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
EP0690873B1 (de) 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Wachstumsfaktor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
JPH10502811A (ja) 1994-07-08 1998-03-17 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−11
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
JP4368522B2 (ja) 1997-07-14 2009-11-18 ユニバーシティー オブ リージ 哺乳動物におけるダブルマスル化を引き起こすミオスタチン遺伝子の変異
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
WO1999024618A1 (en) 1997-11-10 1999-05-20 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
WO1999040181A1 (en) 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
AU778470B2 (en) 1999-07-20 2004-12-09 Pharmexa A/S Method for down-regulating GDF-8 activity

Also Published As

Publication number Publication date
US6369201B1 (en) 2002-04-09
CA2323607C (en) 2009-12-22
PT1056845E (pt) 2007-04-30
DK1056845T3 (da) 2007-05-29
EP1770162A1 (de) 2007-04-04
EP2018871A1 (de) 2009-01-28
AU2507399A (en) 1999-09-06
EP1056845B1 (de) 2007-01-24
EP2018871B1 (de) 2014-10-08
CA2687533A1 (en) 1999-08-26
DE69934970D1 (de) 2007-03-15
IL137831A0 (en) 2001-10-31
CA2687533C (en) 2016-02-02
ES2280115T3 (es) 2007-09-01
ATE419353T1 (de) 2009-01-15
CY1108074T1 (el) 2014-02-12
JP2002504326A (ja) 2002-02-12
US20030065137A1 (en) 2003-04-03
EP1770162B1 (de) 2008-12-31
CA2323607A1 (en) 1999-08-26
AR019818A1 (es) 2002-03-20
ES2527410T3 (es) 2015-01-23
DE69934970T2 (de) 2007-10-25
AU765014B2 (en) 2003-09-04
DK1770162T3 (da) 2009-04-14
ES2318654T3 (es) 2009-05-01
DE69940230D1 (de) 2009-02-12
PT1770162E (pt) 2009-03-24
ATE352619T1 (de) 2007-02-15
BR9907995A (pt) 2001-05-15
CY1108889T1 (el) 2014-07-02
WO1999042573A1 (en) 1999-08-26
NZ506911A (en) 2003-09-26
EP1056845A1 (de) 2000-12-06
KR20010041111A (ko) 2001-05-15

Similar Documents

Publication Publication Date Title
ZA991369B (en) Immunological methods to modulate myostatin in vertebrate subjects.
DE69823439D1 (de) In Wasser zersetzbares Wischtuch
DE69927412D1 (en) Phosphitadditive in polyolefinen
GB9811082D0 (en) Improvements in phase-separation etc.members
HK1045639A1 (en) Sliding reconstitution device.
EP0981872A4 (de) Teilnehmeranschluss-karte mit modem interface
ZA983167B (en) Liquid antacid compositions.
GB2330464B (en) Demodulating device
GB2333413B (en) Moving image restoration
EP1136798A4 (de) Photodetektorvorrichtung
GB9700962D0 (en) Improvements in optical devices
GB9804833D0 (en) Improvements in alignment techniques
GB9908789D0 (en) Improvements relating to film scanners
GB9812966D0 (en) Improvements relating to cards
IL119568A0 (en) Wiping device
AU2552499A (en) Cleaning device for information-bearing cards
GB9607997D0 (en) Improvements in or relating to screens
TW370186U (en) Alignment device
GB9817645D0 (en) Stopper
GB9617799D0 (en) Leaflet/form retaining device
TW440008U (en) Device for securing interface cards
GB9806972D0 (en) Improvements in or relating to securing devices
TW309164U (en) Card having the structure to stop sliding
GB9815253D0 (en) Improvements in or relating to fixing devices
EP1060438A4 (de) Kameras